Compare HAFC & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HAFC | TBPH |
|---|---|---|
| Founded | 1982 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 821.2M | 824.9M |
| IPO Year | 2000 | 2013 |
| Metric | HAFC | TBPH |
|---|---|---|
| Price | $30.36 | $16.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $32.17 | $18.40 |
| AVG Volume (30 Days) | 228.0K | ★ 307.5K |
| Earning Date | 04-21-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.75% | N/A |
| EPS Growth | 22.44 | ★ 279.13 |
| EPS | ★ 2.51 | N/A |
| Revenue | ★ $270,165,000.00 | $15,386,000.00 |
| Revenue This Year | $18.65 | $8.46 |
| Revenue Next Year | $7.28 | N/A |
| P/E Ratio | $12.12 | ★ $8.25 |
| Revenue Growth | ★ 15.28 | N/A |
| 52 Week Low | $21.84 | $8.33 |
| 52 Week High | $31.33 | $21.03 |
| Indicator | HAFC | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 63.93 | 59.74 |
| Support Level | $26.13 | $16.14 |
| Resistance Level | $31.33 | $17.24 |
| Average True Range (ATR) | 0.74 | 0.40 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 75.79 | 85.51 |
Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.